Amarin (NASDAQ:AMRN - Get Free Report) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Tuesday.
Amarin Stock Performance
NASDAQ AMRN traded up $0.01 during trading hours on Tuesday, hitting $0.61. 922,387 shares of the company traded hands, compared to its average volume of 1,035,304. The business's 50-day moving average is $0.53 and its 200-day moving average is $0.57. Amarin has a twelve month low of $0.43 and a twelve month high of $1.36. The stock has a market capitalization of $251.49 million, a price-to-earnings ratio of -6.80 and a beta of 1.83.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Arkfeld Wealth Strategies L.L.C. boosted its stake in shares of Amarin by 52.6% during the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 20,000 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new position in shares of Amarin during the 4th quarter worth approximately $36,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Amarin by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 29,992 shares during the period. Generation Capital Management LLC bought a new position in shares of Amarin during the 4th quarter worth approximately $50,000. Finally, Kornitzer Capital Management Inc. KS boosted its stake in shares of Amarin by 80.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 42,700 shares during the period. 22.25% of the stock is owned by institutional investors and hedge funds.
About Amarin
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Read More
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
